Uncovering low-dimensional, miR-based signatures of acute myeloid and
  lymphoblastic leukemias with a machine-learning-driven network approach by Candia, Julián et al.
  
Title:  
 
Uncovering low-dimensional, miR-based signatures of acute myeloid and 
lymphoblastic leukemias with a machine-learning-driven network approach 
 
 
Authors and Affiliations: 
 
Julián Candia1,2,3, Srujana Cherukuri3,4, Yin Guo3, Kshama A. Doshi3, Jayanth R. 
Banavar2, Curt I. Civin3, Wolfgang Losert2 
 
1 Center for Human Immunology, Autoimmunity and Inflammation, National Institutes of 
Health, Bethesda, MD 20892, USA  
2 Department of Physics, University of Maryland, College Park, MD 20742, USA 
3 Center for Stem Cell Biology & Regenerative Medicine, Departments of Pediatrics and 
Physiology, University of Maryland School of Medicine, Baltimore MD 21201, USA 
4 Noble Life Sciences, 22 Firstfield Rd, Gaithersburg, MD 20878, USA 
 
 
Corresponding Author: 
 
Julián Candia 
Address: Center for Human Immunology, Autoimmunity and Inflammation, National 
Institutes of Health, 10 Center Drive, 10/7N115, Bethesda, MD 20892, USA  
Email: julian.candia@nih.gov 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Abstract 
 
Complex phenotypic differences among different acute leukemias cannot be fully 
captured by analyzing the expression levels of one single molecule, such as a miR, at a 
time, but requires systematic analysis of large sets of miRs. While a popular approach 
for analysis of such datasets is principal component analysis (PCA), this method is not 
designed to optimally discriminate different phenotypes.  Moreover, PCA and other low-
dimensional representation methods yield linear or non-linear combinations of all 
measured miRs. Global human miR expression was measured in AML, B-ALL, and T-
ALL cell lines and patient RNA samples. By systematically applying support vector 
machines to all measured miRs taken in dyad and triad groups, we built miR networks 
using cell line data and validated our findings with primary patient samples. All the 
coordinately transcribed members of the miR-23a cluster (which includes also miR-24 
and miR-27a), known to function as tumor suppressors of acute leukemias, appeared in 
the AML, B-ALL and T-ALL centric networks. Subsequent qRT-PCR analysis showed 
that the most connected miR in the B-ALL-centric network, miR-708, is highly and 
specifically expressed in B-ALLs, suggesting that miR-708 might serve as a biomarker 
for B-ALL. This approach is systematic, quantitative, scalable, and unbiased. Rather 
than a single signature, our approach yields a network of signatures reflecting the 
redundant nature of biological signaling pathways. The network representation allows 
for visual analysis of all signatures by an expert and for future integration of additional 
information.  Furthermore, each signature involves only small sets of miRs, such as 
dyads and triads, which are well suited for in depth validation through laboratory 
experiments. In particular, loss- and gain-of-function assays designed to drive changes 
in leukemia cell survival, proliferation and differentiation will benefit from the 
identification of multi-miR signatures that characterize leukemia subtypes and their 
normal counterpart cells of origin. 
 
 
 
  
  
1. Introduction  
 
Interdisciplinary research at the crossroads of physics, biology, mathematics, and 
informatics are best exemplified by complex network science [1-3]. From early efforts to 
describe the complex, large-scale, networked structure of metabolic, transcription 
regulatory and protein-protein interaction networks [4-8], the emergent network biology 
field has evolved to play a key role in cancer systems biology and systems biology at 
large [9-11]. Within this broad context, here we develop a framework that naturally 
integrates machine learning and complex network ideas into microRNA cancer biology. 
 
MicroRNAs (miRs) are a class of short noncoding RNAs that target messenger RNAs to 
regulate gene expression post-transcriptionally. Expression of miRs is altered in acute 
leukemias [12], and miR signatures for different leukemia types have been found either 
by using large-scale clustering approaches [13,14], which aim at identifying large, highly 
correlated groups of differentially expressed miRs and thus inferring relevant pathways, 
or by focusing on single miRs to find statistically significant population differences 
[12,15-17]. This study addresses the gap between the encompassing view of the 
entire miR landscape offered by clustering techniques, and the narrowly focused 
perspective of single-miR-based analysis, providing a low-dimensional, multi-
miR-based analysis method able to characterize differences between leukemia 
types.  The output is a network of small sets of miRs suitable for phenotyping, 
rather than a unique disease identifier, reflecting the inherent complexity of the 
disease and the redundancy of the blood/immune system. 
 
Low-dimensional representations of high-dimensional data can be obtained by means of 
standard statistical methods such as principal component analysis and singular value 
decomposition, although these approaches are not designed to separate different 
classes optimally [18]. Moreover, these and more recent methods (e.g. self-organizing 
maps [19] and multidimensional scaling [20,21]), achieve dimensional reduction by 
introducing more abstract descriptions of the system in terms of linear or non-linear 
combinations of the actual measurements, i.e. the number of gene or miR parameters 
that must be measured for phenotyping is not actually reduced.  Furthermore, in the 
context of miR-based separation of phenotypes, the “principal components” that result 
from such low-dimensional procedures typically involve a large number of miRs, making 
a biological interpretation very difficult. The key question of “How many miRs (and which 
miR combinations) are needed to build a signature characteristic of a given acute 
leukemia?” remains largely unanswered by these methods.    
 
In this context, we present a novel approach based on machine learning to reduce the 
number of parameters to manageable small sets of miRs, integrated with a method to 
represent the small sets using complex network representations. This procedure allows 
us to build and visualize multi-miR differential signatures of acute leukemias. Our work 
is focused on finding exhaustive lists of multidimensional miR groupings that 
characterize each of the 3 major types of acute leukemias (acute myeloid leukemia 
  
[AML], B-precursor acute lymphoblastic leukemia [B-ALL], and T-cell acute 
lymphoblastic leukemia [T-ALL]), and visualizing these lists using network 
representations. Our approach is systematic (it searches all possible miR 
combinations), quantitative (it provides a measure of separation between leukemia 
types, so that one can compare quantitatively different miR groupings), scalable to 
larger group sizes (we analyze miR dyads and triads, which suffice to characterize all 3 
acute leukemia types; however, the method can be applied to higher-dimensional miR 
groupings, e.g. miR tetrads), and unbiased (it treats every miR on an equal footing, 
without any a priori biological assumptions, although known biology could be used to 
bias the algorithm in a controlled fashion). We learn the multi-miR signatures based on 
data from well-characterized leukemia cell lines; then, we apply the learned patterns to 
primary patient leukemia samples, in order to determine the ability to predict and 
classify acute leukemias based on those signatures. 
 
The experimental and analytic methods are described in the next Section. In the 
“Results and Discussion” Section, we describe some of the common approaches to 
analyze high-dimensional datasets, discuss their shortcomings and the need for a new 
approach, and present the new method to obtain AML-, B-ALL-, and T-ALL-specific 
multi-miR differential signatures. In the final Section, we summarize our findings.  
 
2. Methods 
 
2.1. Cell lines and primary cells 
Precursor B-cell ALL, T-cell ALL, and AML cell lines (KASUMI1, K562, U937, KG1a, 
ML2, MO7e1, HL60 (AML), KOPN8, REH, RCHACV, KASUMI2, MHHCALL3, 
MHHCALL4, MUTZ5, NALM6, SUPB15 (B-ALL), JURKAT, CCRFCEM, MOLT3, 
MOLT16, KARPAS45 (T-ALL)) were purchased from American Type Cell Culture  
(ATCC, Manassas, VA, USA) and Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (DSMZ, Braunschweig, Germany) and cultured according to the 
supplier’s recommendations. Primary leukemia samples were obtained from 
cryopreserved primary samples or obtained from spleens of immunodeficient mice 
which had been transplanted with patient leukemia cells [22]. Primary CD34+ cells from 
mobilized peripheral blood from normal donors were purchased from the Hematopoietic 
Cell Processing Core (Fred Hutchinson Cancer Institute). Primary mature B 
lymphocytes, T lymphocytes, monocytes and granulocytes were purified from peripheral 
blood obtained from healthy adult human volunteers after informed consent following an 
Institutional Review Board-approved protocol (University of Maryland School of 
Medicine). 
 
2.2. Isolation of RNA and miR profiling 
Total RNA was extracted using miRNeasy Midi Kits (Qiagen, Valencia, CA) according to 
the manufacturer’s guidelines. The quality of the isolated RNA was assessed using an 
Agilent 2100 Bioanalyzer. miR levels were measured using microarray analysis; ~500 
ng RNA per sample was hybridized to each GeneChip miRNA 2.0 Arrray (Affymetrix, 
  
Santa Clara, CA) which contained 46,228 probes for the miRs of 71 organisms.  RNA 
labeling, hybridization to arrays, washing, staining, and signal amplification were 
performed according to manufacturer’s instructions in the core facilities of the University 
of Maryland School of Medicine.  
 
2.3. qRT-PCR Analysis  
RNA was isolated from cells suspended in Triazol using miRNeasy kits (Qiagen, 
Valencia, CA) according to the manufacturer’s protocol. Levels of mature miRs were 
measured in a 7900 Real-Time PCR System (Applied Biosystems) using TaqMan qRT-
PCR (Applied Biosystems). U18 was used as an endogenous housekeeping gene 
control due to its consistent expression in acute leukemia cell lines. miR expression in 
every cell line was represented as Ct values, i.e. cycle number at which fluorescent 
signal crosses the pre-set threshold.  
 
2.4. Data Analysis 
Analysis of miR expression was performed using Partek Genomic Suite (Partek Inc., St. 
Louis, MO). The miR array expression data was normalized by means of robust multi-
chip average (RMA) method, generating log2 transformed intensity values. Using this 
method we assessed 847 human miRs. In order to exclude the miRs that significantly 
and consistently express below detection levels, we further filtered based on miR 
expression with mean intensity ≥1 and ≤14, yielding 370 miRs [23,24]. We performed 
SVD dimensional reduction analysis by implementing the function ‘svd’ in R, which relies 
on the package MASS [25]. We performed Support Vector Machine analysis by 
implementing the function ‘ksvm’ in R, which is included in the package ‘kernlab’ [26]. 
We performed a pre-selection of Top miRs for the triad analysis using the Comparative 
Marker Selection and Comparative Marker Selection Viewer modules from the 
GenePattern Genomics Analysis suite [27]. Complex network images were produced 
using Cytoscape [28]. Our analysis framework was integrated by custom-written scripts 
in R, pro Fit, and Perl.  
 
3. Results and Discussion 
 
3.1. The importance of low-dimensional, miR-based signatures of acute 
leukemias 
MiR expression was measured on AML, B-ALL, and T-ALL cell lines and primary patient 
samples. Initially, a set of 847 human miRs was measured for each sample; however, 
here and throughout, we focus on a subset of 370 miRs obtained after filtering out miRs 
with consistently low or absent expression (more details are provided in the Methods 
Section). For each cell line, 3 or 4 replicate measurements were taken. We tested the 
robustness of the replicate datasets by calculating Euclidean distances in the 
multidimensional miR-measurement space. We found that each replicate lay closer to 
the centroid of the remaining replicates from the same cell line, relative to its distance to 
the centroids of each of the other cell lines. All replicates passed this robustness test 
  
(see Supporting Information Text S1 and Supporting Information Figures S1-S4 for more 
details). 
 
Since samples are described by sets of 370 miR expression values, they can be 
represented as dots in a 370-dimensional space, where each axis in this high-
dimensional representation corresponds to one specific miR. Naturally, such a high-
dimensional representation cannot be visualized and, moreover, is of little help to 
convey the essential information oftentimes needed: Which and how many miRs need 
to be measured in order to fully distinguish one leukemia type from another? How 
accurately can these miR signatures, learned from leukemia cell lines, be used to 
classify various types of primary leukemia patient samples? 
 
Principal Component Analysis (PCA) and Singular Value Decomposition (SVD) are 
standard methods for dimensional reduction, which select the directions of largest 
spread of the data and allow a low-dimensional representation that can be more easily 
handled and visualized. In the case where principal components are calculated from the 
covariance matrix, there is a direct relation between PCA and SVD: singular vectors 
from the SVD analysis then agree with the principal components from the PCA analysis, 
and the squared singular values become proportional to the variances of the principal 
components [29]. These techniques for dimensional reduction are powerful and have 
been used widely for analysis of microarray data [18,30-32]. Fig. 1(a) shows a 
PCA/SVD 2D representation of miR expression from AML (red), B-ALL (blue), and T-
ALL (green) cell lines, where different replicate measurements from the same cell line 
are shown with the same symbol. However, in order to find a multi-miR signature that 
could be used to classify different leukemia subtypes, the PCA/SVD method suffers 
from limitations and shortcomings that require a different approach.  
 
The main limitation of the PCA/SVD method is that the eigenmodes (such as modes 1 
and 2 in Fig. 1(a)) are linear combinations of all the miRs in the original data.  Thus, it is 
far from straightforward to interpret these leading characteristic modes in terms of 
specific miRs potentially useful for diagnosis or as targets for treatment. For instance, 
Fig. 1(b) shows the expansion coefficients of modes 1 and 2 in terms of the top 25 miRs 
that contribute to each mode. Clearly, many miRs contribute significantly to the leading 
eigenmodes; for instance, the number 25 miR contributing to mode 1 (namely, miR-93*) 
has a coefficient whose absolute value is 78% of the coefficient associated with the 
number 1 contributing miR (namely, miR-92a). Therefore, mode 1 is associated with 
many miRs; similar observations can be made on the relative contributions of the 
leading miRs in mode 2. In the case of other methods such as self-organizing maps 
[19,33], isomap [34], local embedding [35], and multidimensional scaling [20,21], the 
dimensionality-reduction process introduces non-linear transformations of the instance 
space, which suffers from similar limitations. Furthermore, although the PCA/SVD 
method is designed to find the directions of largest spread, it is not optimized to find the 
directions of largest separation between different data classes. Usually, the PCA/SVD 
low dimensional representation is informative of distinct data clusters (e.g. AML cell 
  
lines form an extended cluster of points on the lower region of Fig. 1(a), while B-ALL 
and T-ALL cell lines appear mostly on the upper region), but the PCA/SVD method is 
not designed to achieve class separation. Moreover, the separation of data classes may 
require dimensions higher than 3D, for which a visualization using PCA/SVD would not 
be possible. 
 
In Fig. 1(c), miRs expressed in patients diagnosed clinically with AML (red), B-ALL 
(blue), and T-ALL (green) are represented in 2D using the same 2 modes from Fig. 1(a). 
The spatial distribution of patient samples by leukemia type is similar to that observed 
for cell lines, although somewhat more spread out and overlapping. Gene expression 
profiling has shown consistent differences between primary clinical samples of human 
leukemias and their model cell lines, where the former appeared to overexpress genes 
related to the immune response, while the latter showed higher expression of genes 
related to macromolecular metabolism [36]. However, after eliminating other cell-line-
specific signatures (proliferation, immortalization, etc.), additional molecular profiling 
studies have shown that characteristic genomic aberrations were conserved across 
leukemic clinical and cell line samples, and these signatures were quite robust, as 
expression data from cell lines correlated highly with previously published data [37]. 
Therefore, our working hypothesis is that differential miR signatures learned from cell 
line data can be meaningfully used as predictors of clinical specimen classification.  
 
By comparing, one miR at a time, the distribution of miR expression values from 
different acute leukemia types, we observe that the distributions overlap with each 
other: That is, we cannot fully separate e.g. AML samples from B-ALL and T-ALL 
samples based only on the expression level of any one miR. Thus, we test whether 
taking two or more miRs simultaneously into account achieves separation. Using two or 
more miRs, the separation between samples of different classes can be assessed by 
means of standard machine learning methods. Machine learning approaches such as 
Support Vector Machines (SVMs) have been tailored as methods of gene selection for 
cancer classification [38]. In this work we use a Support Vector Machine with a linear 
kernel, which is equivalent to the machine learning method known as the perceptron 
[39,40], in order to avoid overfitting and, moreover, to obtain a straightforward 
interpretation of the machine-learned parameters in terms of the original measurements 
[41,42]. Since this approach relies heavily on statistics, we used all cell line replicate 
measurements as classification instances in the learning phase (24 samples from AML, 
36 from B-ALL, and 20 from T-ALL cell lines). As shown in the outlier analysis (see 
Supporting Information Text S1 and Supporting Information Figures S1-S4), all 
replicates passed the robustness test and are considered faithful representatives of their 
parent cell lines.  
 
3.2. AML-centric miR-dyad networks 
Let us first consider AML-centric multi-miR signatures. For each pair of miRs, we 
perform an SVM analysis to determine whether samples are linearly separable based 
on the leukemia types (i.e. we determine whether a straight line boundary exists to fully 
  
separate the AML vs B-ALL cell lines, as well as the AML vs T-ALL cell lines). If the 
leukemia-type-specific samples are not separable, we disregard that given miR pair, 
whereas if the samples are separable, we label that given pair as a “miR dyad” and we 
compute the gap distance (classifier margin) between the different classes. We verify 
the robustness of the linear separation by applying leave-one-out cross-validation. By 
repeating this procedure over the 68,265 pairwise combinations from the initial set of 
370 miRs, we generate a so-called “AML-centric dyad network”. Let us point out that 
other machine learning implementations are possible, e.g. soft-margin and non-linear 
classifiers, which would extend the current application to scenarios that tolerate class 
overlaps due to noise in the datasets. Those model extensions are beyond the scope of 
the present paper. The constraint to strictly linearly separable classes leads to a 
straightforward implementation that, despite its relative simplicity, is able to capture the 
redundancy of multi-miR signatures. 
 
Fig. 2(a) shows the AML-centric miR-dyad network obtained with cell line data, where 
any connected pair of miRs achieves separation between AML and B-ALL (blue links) 
as well as between AML and T-ALL (red links) cell lines. The link width reflects the gap 
distance between different classes (i.e. the width of the boundary determined by the 
support vectors of each class), which is a measure of the goodness of the class 
separation. This network contains 15 nodes (each one corresponding to a different miR) 
and 18 link pairs (each blue/red link pair corresponding to a different miR dyad). The 
miR-dyad network of Fig. 2(a) is a novel type of low-dimensional representation that 
conveys miR-specific information on how to optimally separate different leukemia types, 
unlike the standard PCA/SVD representation of Fig. 1(a).  
 
Let us now validate our findings by analyzing the AML-centric networks in the context of 
the miR literature. A particularly well-studied set of miRs that stands out in our analyses 
is that formed by miR-23a, miR-24, and miR-27a. miR-23a and miR-24 were reported to 
be enriched in CD34+ hematopoietic stem-progenitor cells (HSPCs) [43], and miR-24 
was identified to have a well-defined role as a regulator of normal erythropoiesis via 
targeting of human activin receptor type1, ALK4 [44]. Moreover, miR-23a and miR-24 
both act as tumor suppressors and are down-regulated in multiple cancers. miR-27a is 
co-localized in mammalian genomes with miR-23a and miR-24 [45]; these form the so-
called “miR-23a cluster” that is coordinately transcribed and is under direct negative 
regulation by c-MYC [46]. All 3 miRs in this cluster were reported to be down-regulated 
in acute promyelocytic leukemia, colorectal cancer, prostate cancer, and oral squamous 
cell carcinoma [47-49]. Furthermore, it was recently shown that, by interacting with and 
regulating the pro-apoptotic members of the 14-3-3θ gene family, miR-27a functions as 
a tumor suppressor in acute leukemia [50]. The AML-centric miR-dyad network displays 
all 3 miRs from the miR-23a cluster. Indeed, miR-27, with 9 links, appears as the most 
connected miR in the network, whereas miR-24 has 3 links and miR-23a one 
connection. It should be noted that these miRs are not connected with each other; 
instead, they appear to share neighbors. This result can be understood from the fact 
that two miRs are not connected based on their similarity but rather based on the ability 
  
to fully separate AML from B-ALL and T-ALL. Thus, one might expect that coordinately 
expressed miRs share too much redundant information to make them contribute 
independently to a suitable signature to fully characterize AML. Another interesting 
observation is that all 3 miRs from the miR-23a cluster appear connected to miR-145, 
which is a well characterized miR with tumor suppressor roles reported in a variety of 
cancers [51-53]. Moreover, expression of miR-145 and all its linked miRs in the network 
(namely, miR-23a, 23a*, 24, 27a, 27a* and 130b) has been shown to be involved in 
proliferation and differentiation of hematopoietic cells and to be altered during 
leukemogenesis [54,55].  
 
Fig. 2(b) shows the number of links associated with each miR in the network. We 
observe that the most connected node is miR-27a (with 9 connections), followed by 
miR-145 (with 6 connections); indeed, 14 out of the 18 miR dyads that characterize AML 
vs both B-ALL and T-ALL involve either miR-27a or miR-145. Fig. 3(a) shows the 
distribution of cell line samples for miR-145 vs miR-27a, where, as expected, AML 
samples (red symbols) appear well separated from both B-ALL samples (blue symbols) 
and T-ALL samples (green symbols). As in Fig. 1, different replicate measurements 
from the same cell line are shown with the same symbol. In Fig. 3(b), we show miR-145 
vs miR-27a for patient samples; the pattern of spatial distribution is similar to that for cell 
lines, although with a somewhat larger spread. Indeed, a slight overlap between AML 
and B-ALL is observed in the 27a+/145- region (bottom right corner of Fig. 3(b)). As 
suggested by Figs. 3(a)-(b), we should expect cell lines to be very good predictors of 
clinical sample separation in miR space, although some miR dyads may fail to correctly 
classify a few patient samples, which may actually be at a diagnostic borderline 
between e.g. AML and B-ALL [56].  
 
Fig. 4(a) shows the AML vs B-ALL prediction of clinical samples using AML-centric miR 
dyads. The horizontal axis corresponds to 18 samples from patients diagnosed with 
AML and 29 samples from patients diagnosed with B-ALL, while the vertical axis shows 
the 18 miR dyads from the AML-centric network (Fig. 2(a)). Correctly classified samples 
are shown in green, while incorrectly classified samples are displayed in red. The 
overall prediction performance is very good, with 94% of patients correctly classified 
when considering all of the miR dyads found in cell lines. This matrix representation 
highlights evidence that most failed predictions arise from a few borderline clinical 
samples (namely, patients AML_3, AML_6, AML_8, B-ALL_1, and B-ALL_3) which 
represent only 11% of the samples but concentrate 76% of the total prediction failures. 
Similarly, Fig. 4(b) shows the AML vs T-ALL prediction of clinical samples using AML-
centric miR dyads. In this case, the prediction performance is excellent (99.5% correct). 
 
3.3. B-ALL- and T-ALL-centric miR-triad networks 
In the case of B-ALL-centric networks, there are no miR dyads that fully separate all 
available B-ALL cell line samples from all AML and T-ALL cell line samples. The next 
logical step is to investigate miR triads. However, instead of searching through all 
possible triad combinations, which is very computationally intensive (e.g. N=370 miRs 
  
would require 8.4x106 iterations), here we lay out a framework that is scalable to 
situations where analyzing all possible combinations is outright unfeasible, such as, for 
instance, the case of larger miR datasets (e.g. 1.7x108 triad combinations out of N=1000 
miRs) or the investigation of higher-order groupings (e.g. 7.7x108 tetrad combinations 
out of N=370 miRs). This scalable framework combines our machine-learning-based 
network approach with the class prediction method developed in Ref. [57]. By using an 
implementation of the latter made available by the Broad Institute’s GenePattern 
Genomics Analysis platform [27], each miR is assigned a score that measures its 
significance in a binary classification problem (e.g. classifying B-ALL vs AML samples). 
This set of scores is renormalized by subtracting the mean and dividing by the standard 
deviation of the score distribution (i.e. so that the distribution of renormalized scores has 
zero mean and unit variance). In this way, we obtain two sets of scores, one 
corresponding to the B-ALL vs AML case, the other one to the B-ALL vs T-ALL case. 
We combine them by choosing, for each miR, the lowest score. Notice that, since our 
focus is on achieving full separation of B-ALL from AML and T-ALL, selecting the lowest 
score follows a “weakest-link” rationale that is more appropriate than combining the 
scores by other procedures, e.g. root-mean-square averages. This set of combined 
normalized scores (which we call “GP scores”) is then rank-ordered from most to least 
significant. By selecting the resulting Top-50 miRs in the rank-ordered GP score list, we 
effectively reduce the original dataset to a smaller one, in which the search for relevant 
triad combinations is more tractable. As pointed out above, this framework would also 
be useful for searches of higher-order groupings, such as e.g. miR tetrads.   
 
Based on this Top-50 GP miR list, we apply the machine-learning network method as 
described above, which leads to the B-ALL-centric triad network ensemble shown in Fig. 
5(a). This ensemble consists of several networks, each associated with a hub node 
(shown in red). Triads are formed by adding the hub node to each pair of connected 
nodes in the network; hub nodes from other networks in the ensemble are shown in 
dark yellow. The largest network in the ensemble is associated with the hub node 
representing miR-708; a triad formed by adding miR-708 to any pair of connected nodes 
in this network (for instance, the triad miR-708/503/652) achieves full separation 
between all B-ALL and AML cell line samples, as well as between all B-ALL and T-ALL 
cell line samples. Notice that e.g. miR-503 and miR-652 appear dark yellow in the 
network associated with hub node miR-708, because these nodes are, in turn, hub 
nodes of other networks in the ensemble. This network ensemble contains 191 miR 
triads. Notice, however, that, due to the large number of triads, the gap size between 
leukemia classes cannot be easily represented as link widths (similarly to the AML-
centric dyadic network in Fig. 2(a)). Instead, we provide the full list of class separation 
gap sizes as Supporting Information Dataset S1.  
 
An additional important measure of the role of a given miR is provided by the number of 
triads in which the miR appears. Fig. 5(b) shows, for each node in the network 
ensemble, the number of triads in which the node appears. As mentioned, the most 
connected node is miR-708, which appears in 70% of the triads (133 of the 191 triads in 
  
the network ensemble). Following the learning phase, in which we generated triad 
networks based on data from acute leukemia cell lines, we predicted the classification of 
primary clinical acute leukemia samples. Using all 191 triads from the network 
ensemble, we determined, as a function of the percentage of patients in the cohort (x 
axis), the number of triads that correctly predict a number of patients equal to or larger 
than x. This is shown (for the B-ALL vs AML case) by the red plot in Fig. 5(c). These 
prediction results are compared with average prediction outcomes for 1000 triad sets (of 
191 triads per set) generated from miRs chosen by other methods, namely: triads from 
Top-50 miR lists obtained with GenePattern [27] (labeled “GP Top-50”, blue plot), triads 
from Top-50 miR lists obtained with Support Vector Machine in 370-D (labeled “SVM 
Top-50”, green plot), and triads randomly picked from the full list of 370 miRs (labeled 
“random”, black plot). This comparison shows that the triad network ensemble 
outperforms other methods of miR triad selection in their ability to classify primary acute 
leukemia patient samples. For instance, 177 triads (out of 191) from the triad network 
ensemble are able to predict correctly at least 75% of the patients in the cohort. By 
using the “GP Top-50” method, 136 triads are able to predict correctly the classification 
of at least 75% of the patients, whereas the “SVM Top-50” method provides only 123 
triads above the prediction threshold. By randomly selecting 191 miR triads, only 101 
triads (on average) are able to predict correctly at least 75% of the patients; as 
expected, random selection has the worst performance. Analogously, Fig. 5(d) shows a 
comparison of prediction outcomes in the patient cohort for the B-ALL vs T-ALL case, 
where the triad network ensemble is clearly seen to outperform other methods of miR 
triad selection.  
 
In Fig. 6 we show results pertaining to the T-ALL-centric triad network ensemble. The 
networks shown in Fig. 6(a) contain a total of 136 miR triads that are capable of fully 
separating all T-ALL cell line samples from both AML and B-ALL (see Supporting 
Information Dataset S2 for the full list of class separation gap sizes). The most 
connected node is miR-222, which appears in 55 miR triads (see Fig. 6(b)). These triads 
(learned by using cell lines) show excellent prediction outcomes to classify T-ALL from 
AML primary patient samples (Fig. 6(c)). Indeed, all 136 triads are able to predict 
correctly at least 75% of the patients, 129 triads predict 85% or more of the cohort, and 
102 triads have a prediction outcome of 95% and above. The performances of other 
methods of triad selection are shown for comparison.     
 
The miR-23a cluster (which, as mentioned above, includes miR-23a, 24, and 27a) also 
appears in the miR-triad network ensembles obtained for B-ALL (Fig. 5(a)) and T-ALL 
(Fig. 6(a)), an observation that emphasizes its key role in leukemia. As with the AML-
centric network, no direct links are observed between miRs in the miR-23a cluster, but 
they appear to share many neighbors. For instance, the B-ALL network with hub node 
miR-146a shows miRs 23a, 24, 27a, and others connected to miR-455-3p. This means 
that triads of the form (146a, 455-3p, X) are able to fully characterize B-ALL, where X is 
any miR from the miR-23a cluster. Similarly, the B-ALL network with hub node 455-3p 
shows miRs 23a, 24, 27a, and 193b connected to miR-182, which points to triads of the 
  
form (455-3p, 182, X). In addition to the miR-23a cluster, it is interesting to point out 
other miRs that were shown to play a crucial role in normal and malignant B-lymphoid 
development, e.g. miR-34a, miR-18a, and miR-151 [54,55,58], which also appear in the 
B-ALL-centric triad network. Notice e.g. miR-151-5p, which appears on 51 triads and is 
the second-most connected miR in the B-ALL network, while it is absent altogether from 
the AML and T-ALL-centric networks.   
 
Multi-miR networks may be used as exploratory tools to identify promising miRs and 
guide further experimentation. Indeed, the results for B-ALL (Fig. 5) provide strong 
evidence of the remarkable significance of miR-708, as a biomarker and potentially for 
some function. We performed quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) analysis of relative miR-708 expression levels across all studied 
cell lines to validate the miR microarray results. Figure 7 shows the threshold cycle (Ct 
value) for each cell line, i.e. the number of cycles needed for the measured fluorescence 
to exceed the threshold intensity (see the Methods Section for more details). Indeed, 
miR-708 is up-regulated in most B-ALL cell lines compared with T-ALL and AML, 
suggesting that miR-708 might serve as a biomarker for B-ALL. 
 
3.4. Driving phenotype changes by miR modulation: The need for a multi-miR 
approach 
The association of miR dysfunction with disease phenotypes has given rise to the idea 
that selective modulation of miRs could affect the disease [59]. The feasibility of this 
therapeutic rationale has indeed been confirmed by the striking demonstration that 
inhibition of miR-122 reduces viral load in chronically HCV-infected chimpanzees [60]. 
Attempts to drive phenotype changes with single-miR modulation approaches, however, 
may be misleading, as illustrated by the example of Figure 8. In Figure 8(a), we 
compare the expression levels of miR-23a in CD34+ cells, monocytes and granulocytes 
from healthy donor samples (left box) with AML patient samples (right box). AML 
expression levels of miR-23a are significantly lower than those of healthy donor cells 
(p=0.001). In order to push the miR-23 expression level towards the level in normal 
cells, a miR modulation experiment would increase the expression of miR-23a in the 
AML samples (dotted arrow). However, miR-23a by itself is not able to separate (and, 
hence, fully distinguish) AML samples from those of healthy cell counterparts. Figure 
8(b) shows that miR-23a and miR-24, taken together as a 2D signature, are able to 
achieve separation. The boundary between the healthy and diseased regions is shown 
as a solid line, while a solid arrow shows the direction perpendicular to the boundary. By 
increasing miR-23a, however, an AML sample (such as the one marked with a circle) 
would move along Trajectory I and remain within the diseased region of this 2D 
parameter space. The optimal direction to cross the boundary towards the healthy 
phenotypes is indicated by Trajectory II, which involves decreasing miR-23a and 
increasing miR-24 according a 1:3 ratio. Thus, only by considering a multi-miR signature 
do we observe the optimal trajectory in which we would rightly expect a phenotype 
change. This example illustrates that expectations based on 1D (i.e. single-miR) 
  
approaches may be misleading and shows the need of a multi-miR approach to properly 
design experiments such as selective miR loss- or gain-of-function analysis [61].   
 
4. Conclusions 
 
In this work, we developed a novel dimensional-reduction approach based on machine 
learning and complex network representations, which allowed us to build multi-miR 
differential signatures of the 3 major types of acute leukemias. Starting with AML, we 
found 18 miR dyads that fully separate AML from B-ALL and T-ALL cell lines. We 
visualized our findings through what we call a miR-dyad network that is centered around 
one specific phenotype, in this case AML. Starting with B-ALL or T-ALL, miR dyads did 
not suffice to fully differentiate these leukemias from the other subtypes. Therefore, we 
went on to implement a scalable framework that first preselects the most promising 
miRs based on single-miR analysis, followed by a machine learning approach designed 
to find differential signatures of miR triads. Based on those findings, we computed and 
visualized B-ALL and T-ALL-centric miR-triad network ensembles.  
 
Multi-miR networks provide information on differential molecular signatures 
characteristic of different acute leukemia types. This information can be used in different 
ways. In the context of studies specific to one particular miR, the multi-miR network 
shows which other miRs might be associated with the given miR of interest, leading to 
dyads or triads that together form a distinctive signature. For instance, researchers 
investigating miR-886-3p might use the information from the AML-centric network to 
incorporate miR-27a to their investigations (e.g. by studying the response of leukemia 
cell lines to varying concentrations of exogenous miR-886-3p in combination with miR-
27a).  
 
Alternatively, multi-miR networks can be used as exploratory tools to identify interesting 
miRs and stimulate further experimentation. Indeed, after discovering the remarkable 
features of miR-708 in the B-ALL network, we performed qRT-PCR analyses across all 
studied cell lines, which confirmed that miR-708 was highly and specifically expressed 
in most B-ALLs, hence suggesting that miR-708 might serve as a biomarker for B-ALL. 
These results, indeed, agree with earlier reports on aberrant miR expression profiles in 
childhood ALL [15,62,63]. Schotte et al. [15] report that miR-708 was 250-6500-fold 
more highly expressed in TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and other B-
ALL cases than in MLL-rearranged and T-ALL cases (P<0.01). Han et al. [62] 
investigated the association of dysregulated miRs with childhood ALL clinical outcome 
and found that miR-708 was the most upregulated miR in primary samples obtained at 
the time of leukemia relapse. miR-708 was also found to be associated with in vivo 
glucocorticoid therapy response and with disease risk stratification. Furthermore, Li et 
al. [63] reported significant upregulation of miR-708 in B-ALL samples (P < 0.05) and 
elevated expression of miR-708 in high-risk B-ALL compared to standard- and 
intermediate-risk cases. CNTFR, NNAT, and GNG12 were identified as targets of miR-
708 [63].  
  
 
Finally, we discussed the importance of multi-miR approaches in the context of miR 
modulation experimental design. By comparing AML samples with normal cell 
counterparts (CD34+, monocytes and granulocytes) from healthy donor samples, we 
showed that expectations based on miR-23a alone were misleading. By incorporating 
miR-24 to form a 2D miR signature that fully separates AMLs from normal, we found the 
optimal trajectory to cross the boundary from the AML region to the healthy region, 
which involved decreasing miR-23a, instead of increasing it (as was initially suggested 
by the single-miR analysis based solely on miR-23a).   
 
To the best of our knowledge, this kind of experimental multi-miR approach, informed by 
a systematic and unbiased method such as the one presented in this work, has not 
been reported previously. We believe that identifying a large set of possible pairs or 
triads of phenotype relevant miRs and representing them in a visual way as a network 
has strong potential for discovery research, as well as for clinical diagnosis and 
prognosis. Indeed, although differential diagnosis between AML, B-ALL, and T-ALL is, in 
most cases, successfully achieved by classic histology, flow cytometry biomarkers 
and/or immunohistochemistry, our results suggest that multi-miR panels have the 
potential to be useful diagnosis tools for clinically ambiguous leukemias [13,14]. 
Furthermore, this approach can be applied to comparisons of a leukemia and its healthy 
counterparts, as briefly discussed in Figure 8, and to cohorts with different outcomes 
(e.g. cured vs relapsed patients), thus providing a window into prognosis and the 
quantitative evaluation of disease progression under different treatment strategies.   
 
Finally, let us point out that, although this work has focused on the role of complex 
networks in combination with machine learning as dimensional-reduction and 
visualization tools for data analysis, our framework naturally suggests follow-up studies 
to quantitatively characterize the structure and dynamics of multi-miR networks through 
topological measures such as degree and path length distributions, clustering, 
modularity, assortative mixing, etc [8,64], which may provide valuable systems-level 
insight into molecular processes in health and disease.  
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CAPTION TO FIGURE 1:  
 
Standard methods for dimensional reduction: Principal Component Analysis 
(PCA)/Singular Value Decomposition (SVD). (a) 2D representation of AML (red), B-
ALL (blue), and T-ALL (green) miR expression from cell lines, where different replicate 
measurements from the same cell line are shown with the same symbol. The leading 
eigenmodes capture the directions of largest spread of the data. (b) Each mode in the 
PCA/SVD decomposition is a linear combination of all measured miRs. The rank-
ordered list of the top 25 miRs that contribute to mode 1 is shown on the left-hand side 
table, whereas the top 25 miRs that contribute to mode 2 are shown on the right-hand 
side. Coefficients are normalized so that the sum of absolute values (over all the 370 
measured miRs) equals 100. (c) Using the same 2 modes, miR samples from patients 
diagnosed with AML (red), B-ALL (blue), and T-ALL (green) are represented in 2D.  
 
  
  
 
CAPTION TO FIGURE 2:  
 
AML-centric miR-dyad network obtained with cell line data. (a) Any connected pair 
of miRs achieves separation between AML and B-ALL (blue links) as well as between 
AML and T-ALL (red links). The link width indicates the gap distance between different 
classes. This network contains 18 miR dyads. (b) Degree distribution of the AML dyad 
network, which shows the number of links associated with each miR.  
  
  
 
CAPTION TO FIGURE 3:   
 
Distribution of samples in a 2D miR space: miR-145 vs miR-27a. (a) For cell lines, 
AML (red) samples are well separated from both B-ALL (blue) and T-ALL (green) 
samples. As in Fig. 1, different replicate measurements from the same cell line are 
shown with the same symbol. (b) Patient data are more inhomogeneous: a slight 
overlap between AML and B-ALL is observed in the 27a+/145- region (bottom right 
corner).  
  
  
 
 
CAPTION TO FIGURE 4:   
 
Prediction of patient samples using AML-centric miR dyads. The horizontal axes 
show patient samples, whereas the vertical axes correspond to the 18 miR dyads from 
the AML-centric network. Correctly classified samples are shown in green, incorrectly 
classified samples are displayed in red. (a) AML vs B-ALL case: Classification of 18 
AML and 29 B-ALL patients. (b) AML vs T-ALL case: Classification of 18 AML vs 13 T-
ALL patients.   
  
 
  
  
 
CAPTION TO FIGURE 5:   
 
B-ALL-centric network ensemble of miR triads. (a) Networks obtained with cell line 
data. Each network of pairwise connections has a hub node (in red); triads are formed 
by adding the hub node to each pair of connected nodes. Hub nodes from other 
networks in the ensemble are shown in dark yellow. (b) Number of triads in which each 
node appears. The most connected node is miR-708, which appears in 133 out of 191 
triads. (c) As a function of the percentage of patients in the cohort (x axis), these plots 
show (for the B-ALL vs AML case) the number of triads that correctly predict a number 
of patients equal or larger than x. The prediction results using all triads from the triad 
network (red plot) are compared with average prediction outcomes for 1000 triad sets 
(of 191 triads per set) generated from miRs chosen by other methods, namely: triads 
from Top-50 miR lists obtained with GenePattern [27] (labeled “GP Top-50”, blue plot), 
triads from Top-50 miR lists obtained with Support Vector Machine in 370-D (labeled 
“SVM Top-50”, green plot), and triads randomly picked from the full list of 370 miRs 
(labeled “random”, black plot). (d) Analogously to (c), prediction outcomes on the patient 
cohort for the B-ALL vs T-ALL case, where the triad network is compared to other 
methods of selecting miR triads.  
  
  
 
 
CAPTION TO FIGURE 6:   
 
T-ALL-centric network ensemble of miR triads. (a) Networks obtained with cell line 
data. Each network of pairwise connections has a hub node (in red); triads are formed 
by adding the hub node to each pair of connected nodes. Hub nodes from other 
networks in the ensemble are shown in dark yellow. (b) Number of triads in which each 
node appears out of a total of 136 triads. (c) As a function of the percentage of patients 
in the cohort (x axis), these plots show (for the T-ALL vs AML case) the number of 
triads that correctly predict a number of patients equal or larger than x. The prediction 
results using all triads from the triad network (red plot) are compared with average 
prediction outcomes for 1000 triad sets (of 136 triads per set) generated from miRs 
chosen by other methods, namely: triads from Top-50 miR lists obtained with 
GenePattern [27] (“GP Top-50”, blue plot), triads from Top-50 miR lists obtained with 
Support Vector Machine in 370-D (“SVM Top-50”, green plot), and triads randomly 
picked from the full list of 370 miRs (“random”, black plot). (d) Analogously to (c), 
prediction outcomes on the patient cohort for the T-ALL vs B-ALL case, where the triad 
network is compared to other methods of selecting miR triads.     
  
  
 
CAPTION TO FIGURE 7:   
 
qRT-PCR analysis of relative miR-708 expression levels in B-ALL, T-ALL, and 
AML cell lines. Relative threshold cycles (Ct values), determined by the number of 
cycles needed for the measured fluorescence to exceed the threshold intensity, is 
shown for every cell line. Ct values show that miR-708 is up-regulated in most B-ALL 
cell lines, as compared to T-ALL and AML cell lines. 
  
  
 
CAPTION TO FIGURE 8:   
 
Single- vs Multi-miR approaches to driving phenotype changes by miR 
modulation. (a) Comparison between AML patient data (18 samples) and data for 
normal cell types (22 samples from healthy donors). The p-value is 0.001. The “1-miR 
approach” to modulate AML patient samples based on this information suggests to 
increase miR-23a (dotted arrow). Notice, however, that these populations overlap, 
meaning that miR-23a alone does not suffice to classify an unknown sample as healthy 
or AML. (b) The combination of miR-23a with miR-24 is able to fully classify these 
samples as normal or AML. The SVM boundary (solid line) finds the optimal class 
separation. By increasing miR-23a alone (Trajectory I), an AML sample remains in the 
diseased region. Trajectory II (which involves decreasing miR-23a as miR-24 is 
increased) shows the shortest path to traverse the boundary from the AML region to the 
healthy region.  
 
  
  
Supporting Information Text S1  
 
Outlier analysis of cell-line replicates: centroid distances in multidimensional 
miR-measurement space  
 
MiR expression was measured on 7 AML cell lines (HL60, K562, KASUMI1, KG1a, 
ML2, MO7e1, and U937), 9 B-ALL cell lines (KASUMI2, KOPN8, MHHCALL3, 
MHHCALL4, MUTZ5, NALM6, RCHACV, REH, and SUPB15), and 5 T-ALL cell lines 
(CCRF_CEM, JURKAT, KARPAS45, MOLT16, and MOLT3). Each cell line has been 
measured several times (3 to 4 replicates per cell line). In order to ensure that our 
machine-learning analysis is based on robust data, we developed the following 
robustness test to identify possible outliers. 
 
Let us assume that, for a given disease class, ns samples have been measured from ncl 
different cell lines (e.g. for AML, ns=24 samples have been measured from ncl=7 
different cell lines). Measured samples are labeled by subindex s (s=1,...,ns), while 
different cell lines are labeled by subindex α (α=1,...,ncl). Since samples are described 
by sets of N miR expression values, they can be represented as dots in N-dimensional 
space (in our case, N=370). We renormalize the distribution of measured values for 
each miR (across the ns samples) to have zero mean and unit variance. For each 
sample, we measure: 1) the Euclidean distance (in 370-D miR measurement space 
after renormalization) between that sample and the centroid of the remaining replicates 
for the same cell line, dsin; 2) the Euclidean distance between that sample and the 
centroid of each of the other cell lines, ds,αout. Notice that the centroid of a group of 
objects in N-dimensional space is the mean position obtained by averaging the 
coordinate vectors over all the objects in the group, akin to the definition of the center of 
mass in physics, if all the objects are of equal mass. Supporting Information Figure S1 
shows a schematic representation of the definition of the distances dsin and ds,αout. The 
distance ratio (in logarithmic scale) between replicate r and cell line α is then Rs,α= log 
(ds,αout/dsin). Supporting Information Figures S2-S4 show distance ratios Rr,α/(Rr,α)max, 
which are normalized to have a maximum value of 1.  
 
Supporting Information Figure S2 shows outlier analysis results for AML cell line data, 
where all normalized distance ratios between 24 cell line samples (vertical axis) and 7 
different cell lines (horizontal axis) were calculated based on Euclidean distances in the 
370-dimensional miR measurement space. The block-diagonal structure indicates that 
each sample lies closer to the centroid of the remaining replicates from the same cell 
line, relative to its distance to the centroid of each of the other cell lines. Therefore, we 
conclude that all AML replicates pass the robustness test. Supporting Information Figure 
S3 shows results for B-ALL cell line data (36 samples from 9 different cell lines), while 
Supporting Information Figure S4 displays results for T-ALL (20 samples from 5 different 
cell lines). In all cases, we observe similar block-diagonal matrix values that indicate 
that none of the measured samples should be dismissed as outlier.  
   
  
 
 
CAPTION TO SUPPORTING INFORMATION FIGURE S1:  
 
Schematic representation of the centroid-based method for outlier analysis. 
Assuming for simplicity a 2-dimensional measurement space, each filled symbol 
represents a sample. Red circles represent replicates from cell line 1, blue squares 
represent replicates from cell line 2. The centroids for each group are shown by open 
symbols. The distance between the test sample and the centroid obtained from the 
remaining replicates of cell line 1 is labeled din. The distance between the test sample 
and the centroid obtained from all replicates of cell line 2 is labeled dout. In (a), din<dout 
and the chosen sample passes the robustness test. In (b), din>dout and the chosen 
sample fails the test, therefore it is considered an outlier in the dataset.    
  
  
 
 
CAPTION TO SUPPORTING INFORMATION FIGURE S2:  
 
Outlier analysis of AML cell line data: 24 replicates from 7 cell lines. Normalized 
distance ratios between cell line replicates (vertical axis) and cell lines (horizontal axis) 
based on Euclidean distances in the 370-dimensional miR measurement space. The 
block-diagonal structure indicates that each replicate lies closer to the center of mass of 
the remaining replicates from the same cell line, relative to its distance to the center of 
mass of each of the other cell lines. 
  
  
 
 
CAPTION TO SUPPORTING INFORMATION FIGURE S3:  
 
Outlier analysis of B-ALL cell line data: 36 replicates from 9 cell lines. Normalized 
distance ratios between cell line replicates (vertical axis) and cell lines(horizontal axis) 
based on Euclidean distances in the 370-dimensional miR measurement space. As in 
Fig. S2, the block-diagonal structure indicates that all replicates pass the robustness 
test.   
  
  
 
 
CAPTION TO SUPPORTING INFORMATION FIGURE S4:  
 
Outlier analysis of T-ALL cell line data: 20 replicates from 5 cell lines. Normalized 
distance ratios between cell line replicates (vertical axis) and cell lines(horizontal axis) 
based on Euclidean distances in the 370-dimensional miR measurement space. As in 
Figs. S2 and S3, the block-diagonal structure indicates that all replicates pass the 
robustness test.  
 
 
 
 
